Steve Vignocchi

Role: Tonix Pharmaceuticals
Location: Louisville, KY, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Steve Vignocchi

Specialties: Quality Assurance, Clinical Trial Administration, Document Controller, 21…

Experience

Tonix Pharmaceuticals
Present

Education

Lake Forest College
B.A., American Studies
1989 — 1993

Skills

Supervisory Skills
Creative Writing
Community Outreach
Outlook
Copywriting
Museums
Adobe Acrobat
Nonprofits
Wordpress
Customer Relations
Social Networking
Archival
Training
Volunteer Management
Photography
Blogging
Powerpoint
Research
Cataloging
Software Documentation
Social Media
Microsoft Office
Technical Writing
Libraries
Writing
Newsletters
Protocol
Collections Management
Publishing
Microsoft Word
Word
Public Speaking
History
Customer Service
Higher Education
Library
Facebook
Digitization
Grant Writing
Photoshop

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@tonixpharma.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Tonix Pharmaceuticals

Pharmaceutical Manufacturing · 182 employees · Founded 2007 · Berkeley Heights, New Jersey, United States

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com. *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

tonixpharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Steve Vignocchi

Experience

Education

Lake Forest College

Skills

Find verified contacts for anyone on LinkedIn